Advertisement

Topics

Arrakis Therapeutics Announces $38 Million Series A Financing to Target RNA with Small-Molecule Medicines and Names Michael Gilman Chairman and CEO

07:00 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Veteran management team to re-architect small molecule drug discovery to pursue new RNA targets within vast human transcriptome Arrakis Therapeutics, a pioneering biopharmaceutical company, has completed a $38 million...

Other Sources for this Article

The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com

NEXT ARTICLE

More From BioPortfolio on "Arrakis Therapeutics Announces $38 Million Series A Financing to Target RNA with Small-Molecule Medicines and Names Michael Gilman Chairman and CEO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...